The question appears to be a search for information regarding discounts on Helsinn's drug Akynzeo. However, no specific information about discounts for Akynzeo offered by Helsinn is available in the provided context.
What is Akynzeo?
Akynzeo is a combination antiemetic medication developed by Helsinn. It is used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. The drug combines netupitant, a neurokinin-1 (NK1) receptor antagonist, with palonosetron, a serotonin-3 (5-HT3) receptor antagonist [2].
How does Akynzeo work?
Akynzeo targets two key pathways involved in nausea and vomiting. Netupitant blocks the NK1 receptor, which is activated by substance P, a neurotransmitter involved in the vomiting reflex. Palonosetron blocks the 5-HT3 receptor, a pathway also implicated in nausea and vomiting, particularly acute CINV [1][2]. This dual mechanism aims to provide comprehensive protection against both acute and delayed CINV [1].
When did Akynzeo receive approval?
Akynzeo received approval from the U.S. Food and Drug Administration (FDA) in October 2014 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy [2].
Who manufactures Akynzeo?
Helsinn is the pharmaceutical company that developed and manufactures Akynzeo [1].
What is the patent status for Akynzeo?
Information regarding the specific patent status and expiry dates for Akynzeo is not provided in the given context. Drug patent information can often be found on specialized databases like DrugPatentWatch.com [3].
What are the alternatives to Akynzeo?
Other antiemetic medications are available for preventing CINV. These may include other NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, and other agents, often used in combination regimens [4].
---
1. Helsinn. Akynzeo.
2. FDA approves Akynzeo. U.S. Food & Drug Administration.
3. DrugPatentWatch.com.
4. National Cancer Institute. Antiemetics: Nausea and Vomiting.